Report
EUR 13.93 For Business Accounts Only

An unfavourable environment weighs on EMS-CHEMIE HOLDING, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of EMS-CHEMIE HOLDING (CH), active in the Speciality Chemicals industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date February 15, 2022, the closing price was CHF 931.50 and its target price was estimated at CHF 852.07.
Underlying
EMS-CHEMIE HOLDING AG

EMS-Chemie Holding is a holding company. Through its subsidiaries, Co. engages in the engineering, production and marketing of polymers, fine chemicals and chemical intermediates. Co. also builds industrial plants for chemical processing, develops products for military and civil applications, and operates electric power stations.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch